drugset / Trial / NCT00868413
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with either FCR or BR in subjects with relapsed or refractory chronic lymphocytic leukemia.
Timeline
- Start
- 2009-11
- Primary completion
- 2013-05
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Navitoclax | Small molecule | — | Oral |
| Comparator | Bendamustine | Small molecule | — | Intravenous |
| Comparator | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Comparator | Fludarabine | Small molecule | — | Intravenous |
| Comparator | Rituximab | Monoclonal antibody | — | Intravenous |